We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Korro Bio, Inc. (KRRO - Free Report) shares ended the last trading session 29.7% higher at $12.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.5% loss over the past four weeks.
Korro Bio’s share price gained after the company announced encouraging preclinical results for KRRO-111, an investigational RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). In animal studies, the candidate helped restore functional M-AAT protein while reducing harmful Z-AAT protein in the liver, potentially addressing both lung and liver damage caused by the disease. The therapy also showed strong and sustained activity with subcutaneous dosing. Korro plans to submit a regulatory filing in the first half of 2027, ahead of advancing KRRO-111 into clinical trials.
This company is expected to post quarterly loss of $1.14 per share in its upcoming report, which represents a year-over-year change of +40.6%. Revenues are expected to be $1.5 million, up 37.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Korro Bio, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KRRO going forward to see if this recent jump can turn into more strength down the road.
Korro Bio, Inc. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Journey Medical Corporation (DERM - Free Report) , closed the last trading session 6% higher at $5.09. Over the past month, DERM has returned -26.2%.
For Journey Medical, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.02. This represents a change of +122.2% from what the company reported a year ago. Journey Medical currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
Korro Bio, Inc. (KRRO - Free Report) shares ended the last trading session 29.7% higher at $12.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.5% loss over the past four weeks.
Korro Bio’s share price gained after the company announced encouraging preclinical results for KRRO-111, an investigational RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). In animal studies, the candidate helped restore functional M-AAT protein while reducing harmful Z-AAT protein in the liver, potentially addressing both lung and liver damage caused by the disease. The therapy also showed strong and sustained activity with subcutaneous dosing. Korro plans to submit a regulatory filing in the first half of 2027, ahead of advancing KRRO-111 into clinical trials.
This company is expected to post quarterly loss of $1.14 per share in its upcoming report, which represents a year-over-year change of +40.6%. Revenues are expected to be $1.5 million, up 37.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Korro Bio, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KRRO going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Korro Bio, Inc. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Journey Medical Corporation (DERM - Free Report) , closed the last trading session 6% higher at $5.09. Over the past month, DERM has returned -26.2%.
For Journey Medical, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.02. This represents a change of +122.2% from what the company reported a year ago. Journey Medical currently has a Zacks Rank of #3 (Hold).